These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26952360)

  • 1. The role of tenofovir alafenamide in future HIV management.
    Antela A; Aguiar C; Compston J; Hendry BM; Boffito M; Mallon P; Pourcher-Martinez V; Di Perri G
    HIV Med; 2016 May; 17 Suppl 2():4-16. PubMed ID: 26952360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
    Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
    Shafran SD; Di Perri G; Esser S; Lelièvre JD; Parczewski M
    HIV Med; 2019 Jun; 20 Suppl 7():1-16. PubMed ID: 31099116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
    Sax PE; Zolopa A; Brar I; Elion R; Ortiz R; Post F; Wang H; Callebaut C; Martin H; Fordyce MW; McCallister S
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):52-8. PubMed ID: 24872136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir Alafenamide.
    Gibson AK; Shah BM; Nambiar PH; Schafer JJ
    Ann Pharmacother; 2016 Nov; 50(11):942-952. PubMed ID: 27465879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
    Ogbuagu O
    Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
    Bonora S; Calcagno A; Trentalange A; Di Perri G
    Expert Opin Pharmacother; 2016; 17(3):409-19. PubMed ID: 26642079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tenofovir alafenamide fumarate - a new generation of tenofovir].
    Snopková S; Havlíčková K; Husa P
    Klin Mikrobiol Infekc Lek; 2016 Sep; 22(3):111-117. PubMed ID: 27907972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA; Cherian SM; Özdener AE
    J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    J Clin Virol; 2018 Jun; 103():37-42. PubMed ID: 29627709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Ray AS; Fordyce MW; Hitchcock MJ
    Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
    Rashbaum B; Spinner CD; McDonald C; Mussini C; Jezorwski J; Luo D; Van Landuyt E; Brown K; Wong EY
    HIV Res Clin Pract; 2019 Feb; 20(1):24-33. PubMed ID: 31303147
    [No Abstract]   [Full Text] [Related]  

  • 16. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
    Lee SS; Havens JP; Sayles HR; O'Neill JL; Podany AT; Swindells S; Scarsi KK; Bares SH
    BMC Infect Dis; 2018 Jul; 18(1):310. PubMed ID: 29980192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
    Stellbrink HJ; Lazzarin A; Woolley I; Llibre JM
    HIV Med; 2020 Mar; 21 Suppl 1():3-16. PubMed ID: 32017355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
    Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
    J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
    Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
    AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.